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Abstract 
Background: This two-phase experimental study was conducted to determine the maximum safe dose of intravit-
real imatinib (IVI) and its inhibitory effect on a rat model of choroidal neovascularization (CNV).
Methods: In phase I, 60 rats were divided into six groups (A to F); five of which received IVI with concentrations of 
330 (A), 250 (B), 165 (C), 80 (D), and 40 (E) µg/5 µl, and the control group (F) received balanced salt solution (BSS). In 
addition to electroretinography (ERG), routine histopathological analysis and immunohistochemistry for glial fibrillary 
acidic protein were performed. In phase II, CNV was induced by laser photocoagulation in 25 rats and the animals 
were divided into two groups. One group received the maximum safe dose of IVI, determined in phase I, and the 
other received intravitreal BSS. After 4 weeks, the groups were compared in terms of mean scores of fluorescein leak-
age in fluorescein angiography and the mean CNV areas in histopathological sections.
Results: In phase I, ERG and the histopathological findings revealed retinal toxicity in groups A to D and A to C, 
respectively; therefore, a dose of 40 µg/5 µl imatinib was specified as the maximum safe dose for phase II. In phase II, 
late phase fluorescein leakage and the CNV areas were not significantly different between the imatinib-treated eyes 
and the controls (p = 0.62 and p = 0.5, respectively).
Conclusions: Despite the safety of IVI with a dose of 40 µg/5 µl, no inhibitory effect on laser-induced CNV was 
observed. Further studies are required to investigate the possible synergistic effects of Imatinib with conventional 
anti-CNV drugs.
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Background
Age-related macular degeneration (AMD) is the lead-
ing cause of legal blindness in patients aged over 65 [1] 
and the most common cause of blindness in the Western 
world [2]. Approximately 10  % of AMD patients mani-
fest with the neovascular form of the disease [2]. It has 
been shown that the vascular endothelial growth factor 
(VEGF) is the most important cytokine in both physi-
ological and pathological angiogenesis, which leads to the 
formation of choroidal neovascularization (CNV) [3–5]. 
Therefore, nowadays anti-VEGF agents are the mainstay 
of anti-angiogenesis therapy.
Platelet-derived growth factors (PDGF) as the second 
important cytokines involved in angiogenesis [6], facilitate 
the recruitment of pericytes and smooth muscle cells and 
are essential for maturation and stability of the vasculature 
[7, 8]. The PDGF family binds to two different receptors, 
known as the PDGF receptor alpha and beta. The PDGF 
receptors (PDGFR) are tyrosine kinases, with PDGFR-β 
being more extensively expressed in endothelial cells and 
vascular smooth muscle cells [9–11]. Tyrosine kinases are 
important cellular signaling proteins. Multiple tyrosine 
kinases are involved in angiogenesis, including receptor 
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tyrosine kinases such as VEGF and PDGF receptors. 
Receptor tyrosine kinases are essential for the transduction 
of extracellular signals into the cell [6]. Several receptor 
tyrosine kinase inhibitors like sorafenib, cediranib, suni-
tinib, pazopanib were recently approved [12–15]. These 
drugs, by inhibition of VEGF and PDGF signaling, may be 
promising new therapeutic approach to CNV treatment.
Imatinib, a specific inhibitor of tyrosine kinase, was 
approved in 2001 for the treatment of human cancer [16]. 
It downregulates PDGFR signal transduction [17]. In the 
absence of PDGFR signaling, the vascular pericytes strip 
off and the integrity of the vessel wall is compromised. 
These vessels become more sensitive to the withdrawal of 
VEGF, and therefore the vessel regression is more promi-
nent [18–20]. Hence, with this hypothesis that imatinib 
could inhibit or at least slow down the progression of 
CNV, the present study was designed in two phases. In 
phase I, the maximum safe dose of intravitreal imatinib 
was determined in a rat model, and in phase II, the prob-
able inhibitory effect of intravitreal imatinib on laser-
induced CNV was investigated in a rat model.
Methods
Study design and animals
This two-phase study was designed to determine the 
maximum safe dose of intravitreal imatinib (IVI) in phase 
I and its possible inhibitory effect in an animal model of 
laser-induced CNV in phase II. Eighty-five Lister Hooded 
pigmented rats (Razi Institute for Vaccine and Serum 
Research, Karaj, Iran) weighing 200–300 g were included. 
The animals were preserved in plastic cages under a 
12/12-h dark–light cycle, with access to the food and 
water ad  libitum. The research was ethically reviewed 
and approved by ethical committee of Ophthalmic 
Research Center, Shahid Beheshti University of Medical 
Sciences and adhered to the guidelines of the Associa-
tion for Research in Vision and Ophthalmology (ARVO) 
Statement for the use of animals in ophthalmic and vision 
research and Shahid Beheshti Medical University guide-
lines on the use of laboratory animals. For all proce-
dures, the animals were anesthetized with intramuscular 
injection of ketamine hydrochloride (Ketamine-Rotex, 
Rotexmedica, Trittau, Germany) (80  mg/kg) and xyla-
zine hydrochloride (Xylazin, Animedic, Germany) (5 mg/
kg). The pupils were dilated with one drop of tropicamide 
0.5 % (Mydrax, Sina Darou, Tehran, Iran). After last ERG 
and fluorescein angiography in phase I and II respec-
tively, the rats were immediately euthanized by cervical 
dislocation when they were deeply anesthetized.
Preparation of intravitreal imatinib
At the present time, imatinib is marketed only in the 
form of 100 and 400  mg tablets and does not have any 
injectable form. The active substance of the drug is the 
mesylate salt form of imatinib, which is a phenylamino-
pyrimidine derivative in the form of white to slightly yel-
lowish crystalline photostable powder. The solubility of 
imatinib mesylate in aqueous solutions depends on the 
pH and its highest solubility is at pH 5.5–5.8. The stock 
solution of imatinib mesylate (Sigma-Aldrich Chemie 
GmbH, Taufkirchen, Germany) was prepared in ster-
ile distilled water wherein a pH of 5.5–5.8 was reached 
using a tiny amount of sulfuric acid. However, after add-
ing imatinib powder, the pH of final solution was about 
neutral. The amounts of 40, 80, 165, 250 and 330 mg of 
pure powder were weighted in 5  ml volumetric flasks, 
dissolved with the distilled water and then made the 
volume to prepare 40, 80, 165, 250 and 330  µg/5  µl 
concentrations.
Phase I
Sixty rats were categorized into six groups (A to F); of 
which five groups received IVI with concentrations of 
330 (A), 250 (B), 165 (C), 80 (D), and 40 (E)  µg/5  µl in 
the right eye, control group (F) received balanced salt 
solution (BSS). Injections were performed under ster-
ile conditions, using a surgical microscope, by an expert 
ophthalmologist (HN), who was not aware of the doses, 
by using a Hamilton 5 µl glass needle just posterior to the 
limbus. Electroretinography (ERG) examinations were 
carried out at baseline, and then 1 and 4 weeks after the 
injection. After 4  weeks, all rats were euthanized and 
their right eyes were enucleated for histopathological 
analyses. On the basis of the ERG and light microscopic 
results, the maximum safe dose of IVI was chosen for 
phase II.
Electroretinography
Electroretinograms were obtained at the baseline, just 
before injections and at 1 and 4  weeks after imatinib 
injection. All procedures were done in darkness with 
infra-red illumination and image converters. ERG was 
carried out as described before [21]. Briefly, after at least 
2-h dark adaptation, the animals were anesthetized and 
their pupils were dilated. During anesthesia body tem-
perature was maintained between 36 and 37 °C. Then the 
animals were placed in the recording chamber upon a 
temperature-controlled heating pad. To record the ERG 
signals, corneal gold-wire electrodes were implemented. 
The ERG signals were recorded using the RETI-port/
scan 21 electrophysiological diagnostic systems (Roland 
Consult, Brandenburg, Germany). The scotopic and pho-
topic responses were recorded simultaneously in both 
eyes. ERG changes were considered significant if b-wave 
amplitudes were reduced by at least 30 % from the base-
line value [21]. The ERG results at different time points, 
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After the last ERG record, the animals were euthanized 
and their enucleated eyes fixed in 10  % formalin, were 
sent for light microscopic examinations. After bisect-
ing each eye axially into two calottes and embedding in 
paraffin blocks; 5-µm tissue sections were stained with 
hematoxylin and eosin and examined under light micros-
copy (BX41, Olympus, Japan) by two masked ophthalmic 
pathologists (MRK, SBH), in terms of integrity of the 
retinal layers and the presence of retinal hemorrhage, 
inflammation, and atrophy. Moreover, the immunohis-
tochemical study for glial fibrillary acidic protein (GFAP) 
was also performed (polyclonal rabbit anti-glial fibrillary 
acidic protein, DAKO, Denmark) in the groups without 
any histopathological changes. Compared to the controls, 
increased GFAP immune reactivity in the retinal Mul-
ler cells in the treated groups was graded as remarkable 
or unremarkable. Histopathological changes indicating 
the retinal toxicity included: the absence of retinal layer 
integrity, presence of retinal hemorrhage, and/or inflam-
mation, presence of retinal gliosis or atrophy, and the 
presence of remarkable GFAP immune reactivity.
Phase II
Experimental CNV was induced in the right eye of 25 
rats and the animals were randomized into the treatment 
group (14 animals) that received the maximum safe dose 
of IVI determined in phase I, and the control group (11 
animals) that received intravitreal BSS. After 4 weeks, the 
animals underwent fluorescein angiography (FAG) and 
were then euthanized. The CNV areas were assessed by 
performing histopathological examinations.
Laser‑induced choroidal neovascularization
We used pigmented rats as a model for laser induced 
CNV, because rats’ retina is very similar to the human 
retina and it is homogenously pigmented and exhibits a 
high incidence of CNV after photocoagulation [22]. The 
rats were anesthetized and their pupils were dilated, 
as described above. By using a slit lamp infrared diode 
laser delivery system (Microlase, Keeler, Windsor, UK) 
and a noncontact 78 D lens, six laser spots (wavelength, 
810  nm; spot size, 100  µm; duration, 0.1  s; and power, 
150  mW) were applied between the major blood ves-
sels in each eye. Development of a vapor bubble with 
each laser spot pointed to the rupture of the Bruch’s 
membrane.
Fluorescein angiography
Four weeks after laser photocoagulation, fluorescein 
angiography (FAG) was performed to address any sign of 
CNV. Angiograms were taken under general anesthesia 
using a Heidelberg Retina Angiograph (HRA2, Heidel-
berg Engineering, Heidelberg, Germany) after intraperi-
toneal injection of 0.1  ml of 10  % fluorescein sodium 
(Fluocyne, Laboratories SERB, Paris, France). Pictures 
were interpreted by three masked retina specialists (HN, 
AR, RN). Leakage was characterized by the presence of 
a hyperfluorescent lesion on the late-phase angiograms 
and graded as: 0, no leakage; 1, slight leakage; 2, moder-
ate leakage; and 3, prominent leakage [22, 23]. The leak-
age scores of the lesions in any rat were summed to yield 
a single value per rat per one observer. Then the scores 
were averaged between the three observers.
Measurement of the choroidal neovascularization area 
in histopathological sections
The formalin-fixed eyes, as described above, were 
bisected axially and submitted for histological process-
ing. After embedding into paraffin blocks, serial thin 
tissue sections were prepared and stained with hema-
toxylin and eosin. An attempt was made to serially sec-
tion the entire CNV lesion. Sections were examined 
under light microscopy (BX41, Olympus, Tokyo, Japan) 
by two masked ocular pathologists (MRK, SBH). For 
each lesion, the section that was estimated to have the 
largest CNV was chosen and photographed using a 
digital camera (DP12, Olympus, Japan, Tokyo). Images 
were transferred to a computer and the area of CNV 
was delineated and calculated using the ImageJ software 
(ImageJ 1.48).
Statistical analysis
All statistical analyses were performed by SPSS (Ver-
sion 21.0, IBM Co., Chicago, IL, USA). The mixed model 
analysis was used to compare the results before and after 
injections in treated and control eyes. The Kruskal–Wal-
lis test was used to compare the results in the groups 
at baseline. Comparison of the groups by adjusting the 
baseline values was performed by analysis of covariance 
(ANCOVA). Another mixed model was used to com-
pare the leakage quantification, by considering the cor-
relation of the results from the three observers. Also, we 
used regression analysis to obtain the trend of the dos-
age effect on the drug toxicity. In all the above analyses, 
the Bonferroni correction was considered for multiple 
comparisons.
p-values less than 0.05 were considered statistically 
significant.
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Results
Phase I
One rat from each of the groups A, C, and F, two rats 
from the group D, and three from the group E did not 
survive, and therefore, were excluded from the study.
Electroretinography
Table  1 shows the mean of scotopic and photopic ERG 
amplitudes in the study groups at the baseline and 1 and 
4  weeks after IVI. The ERG pattern and implicit times 
were almost identical in all groups. No significant dif-
ferences in the photopic ERG results were observed 
between the groups and also in each group at the speci-
fied time-points of the study (p > 0.05). However, mean 
amplitude of b-wave in scotopic ERG was reduced sig-
nificantly in groups A to D, 4 weeks after IVI (p < 0.05) 
and did not reveal a significant change in groups E and F 
(p > 0.05).
Light microscopy
Histopathological analysis disclosed retinal toxic changes 
in the form of loss of retinal layer integrity and reti-
nal atrophic changes in groups A to C. The histopatho-
logical features and GFAP immune-reactivity were 
unremarkable in groups D and E as compared to the con-
trols (Table 2; Fig. 1). Given the ERG and histopathology 
results, 40 µg/5 µl was chosen as the maximum safe dose 
of IVI for phase II.
Phase II
Out of 25 rats, three rats in the treatment and one in the 
control group expired before the final evaluation.
Choroidal neovascularization scores in fluorescein 
angiography
Four weeks after laser application, FAG revealed the 
development of CNV in the laser-burnt sites. The mean 
score of leakage in the imatinib-injected eyes was not sig-
nificantly different from the controls (p = 0.619) (Fig. 2; 
Table 3).
Choroidal neovascularization areas in histopathological 
sections
The rats treated with IVI showed no significant differ-
ence in neovascular choroidal outgrowth compared to 
those in the controls; this finding was concordant with 
the FAG results. The average CNV area in the imatinib-
treated eyes [mean (SE) 277401.1 (215282.9) µm2; n = 11 
Table 1 Mean scotopic and photopic ERG a- and b-wave amplitudes in different groups at different time points
† Based on Mixed analysis, adjusted for the multiple comparison by Bonferroni method
‡ Based on Mann–Whitney test
* Adjusted for the baseline, based on analysis of covariance






Base Value 22.85 ± 28.57 19.48 ± 20.36 12.47 ± 5.91 12.45 ± 16.98 13.13 ± 9.19 12.86 ± 13.77 0.841‡
Week 1 Value 14.83 ± 11.72 11.17 ± 5.57 8.9 ± 6.59 10.84 ± 8.02 12.22 ± 7.73 10.38 ± 9.21 0.540*
Within P† 0.684 0.528 0.541 1.000 1.000 1.000
Week 4 Value 9.92 ± 4.46 8.25 ± 6.13 6.68 ± 5.73 10.46 ± 5.62 12.66 ± 10.67 8.07 ± 7.17 0.285*






Base Value 39.55 ± 16.06 49.47 ± 16.29 36.25 ± 18.16 34.54 ± 30.04 47.82 ± 32.77 31.13 ± 15.47 0.721‡
Week 1 Value 28.83 ± 10.94 36.38 ± 17.26 28.88 ± 13.28 29.87 ± 17.7 44.72 ± 32.98 30.8 ± 17.31 0.277*
Within P† 0.165 0.523 0.222 1.000 1.000 1.000
Week 4 Value 35.48 ± 17.57 38.45 ± 31.76 26.73 ± 10.26 29.45 ± 12.36 25.18 ± 22.11 30.29 ± 25.66 0.853*






Base Value 77.19 ± 36.94 45.69 ± 24.72 34.43 ± 18.89 47.86 ± 36.06 51.19 ± 17.11 54.33 ± 17.06 0.079‡
Week 1 Value 68.69 ± 38.25 43.15 ± 42.86 31.21 ± 16.94 44.83 ± 24.19 43.18 ± 27.21 24.26 ± 14.82 0.024* F Vs A
Within P† 1.000 1.000 1.000 1.000 0.772 0.000
Week 4 Value 57.89 ± 11.08 54.52 ± 67.42 19.74 ± 15.09 30.86 ± 30.34 32.14 ± 24.89 25.64 ± 13.44 0.135*






Base Value 153.03 ± 83.46 186.2 ± 71.72 145.13 ± 45.81 126.6 ± 43.54 155.41 ± 52.43 154.32 ± 58.28 0.163‡
Week 1 Value 129.98 ± 48.91 169.2 ± 53.28 125.86 ± 87.19 73.5 ± 20.77 98.01 ± 39.99 70.66 ± 44.32 0.003* F Vs C 
& A
Within P†  1.000 1.000 0.928 0.026 0.061 0.000
Week 4 Value 102.13 ± 122.37 142.84 ± 68.11 88.57 ± 61.39 55.95 ± 29.69 90.23 ± 72.82 58.85 ± 41.12 0.195
Within P† 0.626 0.623 0.046 0.001 0.031 0.000
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eyes] was comparable with the control eyes [mean (SE) 
258835.7 (58881.6) µm2; n = 10 eyes] (p = 0.499) (Fig. 3).
Discussion
In the present study, we found 40 µg of IVI as the maxi-
mum safe dose based on the ERG and histological find-
ings. However, we failed to demonstrate any inhibitory 
effect on laser-induced CNV in an animal model, by 
using this dose of intravitreal imatinib. Also, the neovas-
cular membrane size was variable in the treatment group, 
as we can observe with the box plot in Fig. 3. It might be 
related to the number of the rats in the treatment arm. 
Although we included 11 rats and it seemed enough for 
an animal study, this small sample size may be the rea-
son for the scattered distribution noticed in the results 
(CNV areas). In addition, the final size of CNV area may 
be related to both the imatinib inhibitory effect and the 
extent of rupture in the Bruch’s membrane which could 
not be induced equally for all samples.
To the best of our knowledge, this was the first time 
that imatinib was used to inhibit laser-induced CNV 
lesions. Raimondi et  al. recently found that imatinib 
inhibited physiological and pathological retinal angio-
genesis in mice [24]. They revealed that intraperitoneal 
imatinib injection (100 mg/kg/day) for 5 days in an oxy-
gen induced retinopathy (OIR) model of mice signifi-
cantly reduced revascularization of avascular areas and 
effectively inhibited the formation of neovascular tufts 
by targeting neuropilin 1-dependent ABL1 activation in 
endothelial cells. They concluded that imatinib inhib-
ited both physiological and pathological angiogenesis in 
the mouse retina in a VEGF- and VEGFR2-independent 
fashion via ABL1 inhibition. However, systemic usage 
of imatinib may induce both ocular and systemic side 
effects [25, 26]. Additionally, pathological neovascu-
larization in OIR is different from that seen in CNV, in 
which the source of new vessels is choroidal vasculature. 
Some investigators studied the effects of other receptor 
tyrosine kinase inhibitors on laser-induced CNV in rats 
or mice. Park et  al. investigated the effect of sorafenib, 
an orally administered, multi-targeted receptor tyros-
ine kinase inhibitor, on CNV progression in a rat CNV 
model, and showed that the drug inhibited laser-induced 
CNV [27]. Kang and co-workers evaluated the anti-
angiogenic effects of the VEGF receptor tyrosine kinase 
inhibitor, cediranib, in an experimental laser-induced 
CNV model [28]. They found that oral administration 
of cediranib inhibited CNV growth. Pazopanib, a multi-
targeted tyrosine kinase inhibitor was used by Takahashi 
and co-workers to inhibit laser-induced CNV develop-
ment in rats [29]. They noticed that oral pazopanib inhib-
ited CNV development. They also notified that treatment 
of established CNV with pazopanib, either systemically 
or by periocular injection, resulted in the regression of 
CNV. Kami and colleagues used SU5416 in mice, as a 
selective potent inhibitor of the receptor tyrosine kinase, 
intraperitoneally every other day for 14 days and showed 
that SU5416 suppressed fluorescein leakage from the 
photocoagulated lesion and inhibited laser-induced CNV 
formation partially [30]. On the other hand Honda and 
co-workers, in an experimental CNV model, used the 
liposomal form of the SU5416 and disclosed that only a 
single intravitreal injection of the drug reduces the CNV 
area significantly when compared with the control rats 
[31]. Unlike the above-mentioned studies, our survey did 
not show any advantages in using the intravitreal injec-
tion of the PDGF receptor inhibitor, imatinib, in a rat 
model of experimental CNV. This shows that PDGF only 
plays the role of a contributory factor in CNV formation 
and its inhibition per se cannot prevent CNV forma-
tion. Hence, VEGF inhibition seems to be the corner-
stone of CNV inhibition. Furthermore, unlike sorafenib, 
cediranib, pazopanib, and SU5416, as multi-targeted 
tyrosine kinase inhibitors that prevent both PDGF and 
VEGF receptors, imatinib is a specific tyrosine kinase 
inhibitor that inhibits only the tyrosine kinase activity 
of PDGF receptors and does not have any influence on 
VEGF receptors.
In the phase I of the study, 40 µg/5 µl of IVI was deter-
mined as the maximum safe dose. Evaluating the intraoc-
ular toxicity of IVI in rabbits, Kitzmann et al. discovered 
that imatinib at a dose of 1.65 mg/0.1 ml caused exten-
sive retinal histological toxicity in rabbits, while at lower 
doses of 825 µg/0.1 ml and 165 µg/0.1 ml, no sign of tox-
icity was observed [32]. Considering the vitreous vol-
ume in rabbit and rat eyes (1500 vs. 54 µl) we specified 
Table 2 Histopathological and GFAP immune reactivity findings in BSS and imatinib-injected eyes
Group F (N = 9) Group E (N = 7) Group D (N = 8) Group C (N = 9) Group B (N = 10) Group A (N = 9)
Intra and subretinal hemorrhage 0 0 0 0 0 0
Preserved retinal integrity 9 7 7 3 3 1
Preserved RPE integrity 9 7 7 3 4 2
Retinal atrophy 0 0 0 0 7 7
Remarkable GFAP 0 0 0 – – –
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a greater safe dose of IVI compared to the Kitzmann 
report (0.74 vs. 0.55 µg/µl of vitreous volume). Further-
more, it should be noted that in the study by Kitzmann 
et  al., only routine histological examinations were 
implemented to address the safe and toxic doses of IVI. 
They did not evaluate the GFAP immunoreactivity and 
Fig. 1 Histopathological and GFAP immune reactivity features in BSS and imatinib-injected eyes. Note the remarkable retinal layers in BSS-injected 
(a) and 40 µg imatinib-injected (b) eyes (hematoxylin and eosin, magnification ×200). There is severe retinal atrophy and disorganization together 
with pigment migration into the retina in 165 µg (c) and 330 µg (d) imatinib-injected eyes (hematoxylin and eosin, magnification ×200). GFAP 
immunoreactivity, as compared to a BSS-injected eye (e) was not significant in the 40 µg-injected (f) eye (magnification ×400). GFAP glial fibrillary 
acidic protein, BSS balanced salt solution
Page 7 of 10Nikkhah et al. Int J Retin Vitr  (2015) 1:16 
electrophysiological tests, to detect subtle retinal toxicity 
that might have been induced by IVI. Moreover, in com-
parison with our study, they had used greater dose inter-
vals. Dib and co-workers evaluated in  vivo and in  vitro 
toxicity of sunitinib malate, a multi-kinase inhibitor [33]. 
In the in  vivo model, 0.1  cc of sunitinib was injected 
intravitreally in rabbits. No toxicity was observed with 
12.5 mg/ml, but light microscopy showed that the 25 mg/
ml solution damaged the photoreceptors layer. However, 
no functional changes in the electroretinogram were 
observed in any group. There was a disparity between 
Fig. 2 Fluorescein leakage from laser-burnt sites in treatment and control eyes. Infrared fundus photographs and fluorescein leakage from CNV 
lesions in the imatinib-treated (a, b) and control eyes (c, d), 4 weeks after laser application in the rat retina. Note the similar intensity of fluorescein 
leakage in both groups. CNV choroidal neovascularization
Table 3 The fluorescein leakage score in  the treatment 
and control eyes
§ Based on Mixed model consider the correlation of the results for two observer
Control Treatment P value§
Number-leakage
 Mean ± SD 4.6 ± 2 4 ± 1.7 0.266
 Median (range) 5 (1–6) 4 (2–6)
Sum-leakage
 Mean ± SD 8.9 ± 6 9.8 ± 5.1 0.619
 Median (range) 8 (1–18) 9.5 (3–18)
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Fig. 3 Choroidal neovascularization in histopathological sections and mean CNV area in treatment and control eyes. Note the presence of choroi-
dal neovacular tissue (green asterisk) 4 weeks after 40 µg of IVI (a), with no significant difference from what is seen in a BSS-injected (b) eye (hema-
toxylin and eosin, magnification ×200). c The mean CNV area in the control and treatment groups was 258,836 µm2 ± 58,882 (median 247,946 µm2) 
and 277,401 µm2 ± 215,283 (median 236,262 µm2) respectively. The difference was not statistically significant (p = 0.499, based on the Mann–Whit-
ney test). IVI intravitreal imatinib, BSS balanced salt solution, CNV choroidal neovascularization
functional and histopathologic results in 25 mg/ml con-
centration. Furthermore, five rabbits in each group might 
not be enough for toxicity evaluation.
Using a hand-made injectable form of imatinib was a 
shortcoming in our study. In addition, we injected the 
drug simultaneously when applying the laser injuries. 
Knowing that the half-lives of imatinib and its active 
metabolites are 18 and 40 h [34], and the fact that at least 
2  weeks are needed for the laser-induced murine CNV 
to stabilize [35], one may conclude that the injected 
drugs in our study disappeared a long time before they 
had the chance of showing any effect. However, we sup-
posed that the half-life and efficacy of imatinib in the vit-
reous, similar to many other drugs [36–39], would last 
long enough to influence the result. Nonetheless, further 
studies should be conducted to address the half-life of 
imatinib in the vitreous, as well as, the best time for the 
intravitreal injection of imatinib, to increase its inhibi-
tory effect on laser-induced CNV. We injected BSS intra-
vitreally in the control group, as we used a tiny amount 
of sulfuric acid in the imatinib preparation, using a 
neutral solution containing that minute amount of sul-
furic acid in the control group could have been more 
acceptable.
Conclusions
Intravitreal imatinib with the maximum safe dose of 
40  µg/5  µl, which was determined in this study, had no 
inhibitory effect on laser-induced CNV in the rat model. 
However, imatinib might have a synergistic effect on the 
conventional anti-VEGF drugs in the treatment of CNV, 
which needs further investigations.
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